Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
LNAI
Lunai Bioworks Inc.
Lunai Bioworks Inc. (LNAI) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Profitability (C-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.5
/ 5.0
C+
Value
B-
Factor Score
2.9
/ 5.0
Growth
C+
Factor Score
2.5
/ 5.0
Profitability
C-
Factor Score
2.0
/ 5.0
Momentum
C+
Factor Score
2.5
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
N/A
EV / EBITDA
-0.1
Rev Growth YoY
N/A
Gross Margin
N/M
Price Return 3M
N/A
Price Return 12M
N/A
Catalyst Signal
0.00
Market Cap
$829.7K
TTM Revenue
$52.0K
Price / Sales
16.0
ROE
N/A
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (2.9) | C+ (2.5) | C- (2.0) | C+ (2.5) | C+ (2.6) | C+ (2.5) |
| 2026-11-06 | B- (2.9) | C+ (2.5) | C- (2.1) | C+ (2.5) | C+ (2.7) | C+ (2.5) |
| 2026-10-30 | B- (2.9) | C+ (2.5) | C- (2.0) | F (0.6) | C+ (2.7) | C- (2.1) |
| 2026-10-23 | C+ (2.8) | C+ (2.5) | C- (2.0) | D- (1.0) | C+ (2.6) | C (2.2) |
| 2026-10-16 | C+ (2.6) | C+ (2.5) | C- (2.0) | D- (1.1) | C+ (2.6) | C (2.2) |
Page
1
of
4